Itaconix (LSE:ITX), the AIM-quoted maker of plant-based speciality polymers, has reported a first half in which Revenue grew sharply and adjusted EBITDA reached break-even. The central question is why the company has now lifted its revenue expectations for the full year, and what its interim figures reveal about the durability of that improvement.

What Itaconix Does

Itaconix plc (LSE:ITX) develops and sells polymers derived from itaconic acid, a building block produced from plant sugars. The products are used mainly in homecare detergents, where they provide scale inhibition and odour neutralisation. The group reports in US dollars and runs two segments: Itaconix Performance Ingredients, which sells polymers to consumer product makers, and SPARX Formulated Solutions, which offers finished formulations such as detergent tablets. Manufacturing is carried out at a single Facility in North America, while customers are spread across North America and Europe, the Middle East and Africa (EMEA).

The Interim Results of 8 September 2026

On 8 September 2026, the company published results for the six months ended 30 June 2026. It reported revenue of $8.3 million, up 72% year on year, describing this as its fourth consecutive half of growth and a record. Performance Ingredients revenue rose 104% to $6.7 million, while SPARX revenue increased 3% to $1.6 million. Gross Profit rose 74% to $3.0 million, giving a gross Margin of 35.6% against 35.1% a year earlier. Adjusted EBITDA was break-even, compared with a $0.2 million loss in the first half of 2025, and the loss before tax narrowed to $0.3 million from $0.4 million. Operating Cash Flow was a positive $0.9 million, and net cash and investments stood at $5.1 million.

Geographically, the company said EMEA revenue grew 166% and now accounts for 49% of group revenue, and that it secured two large new customers in detergent markets. Management guided to full-year revenue of at least $14.8 million and a small positive EBITDA, and repeated a medium-term ambition of $30 million in revenue.

How the Guidance Has Moved

The interim guidance compares with the outlook in the preliminary results of 24 March 2026, when the company reported 2025 revenue of $10.5 million, up 61%, an adjusted EBITDA loss of $0.6 million and a net loss of $1.4 million, and pointed to 2026 revenue of $13.3 million with positive adjusted EBITDA of $0.3 million. The higher revenue figure suggests first-half Demand ran ahead of the company's earlier planning, although the EBITDA language remains modest.

Commercial news has also accumulated. On 14 July 2026, Itaconix said it had signed its first SPARX Supply agreement for plastic-free dish detergent tablets with a North American brand, with retail availability expected by the end of 2026. Earlier in July it extended an agreement with Bonals Technologies, whose tablet press technology is used alongside Itaconix polymers.

Risks and Points to Watch

The company's own disclosures flag several uncertainties. In its 2025 annual results it said three customers represented 48% of revenue, up from 40% in 2024, so the loss or delay of a major order could weigh heavily on results. It also cited exposure to US-China trade relations in sourcing itaconic acid, together with Tariff and shipping-time pressures on raw material costs and working capital. Reliance on one manufacturing site adds operational risk. Investors may also watch whether SPARX, which grew only slightly in the half, gains traction as tablet agreements convert into retail sales, and whether margins hold as volumes rise.

Conclusion

Itaconix has raised its revenue expectations because, according to its 8 September interim results, first-half sales grew 72% on stronger demand for its performance ingredients, particularly in EMEA, while adjusted EBITDA reached break-even and operating cash flow turned positive. Delivery of the second-half plan, customer concentration and trade-related input costs remain the key tests.